Nivolumab + cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1st line
This interactive virtual meeting will focus on the 9ER trial with the combination of nivolumab + cabozantinib for mRCC patients in first line. It will be chaired by Petri Bono from Finland and we are happy to share that Thomas Powles and Viktor Grünwald will walk us through the data and discuss the landscape.
October 12th
Time: 15:30 – 17:15
